Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSUMM.L Share News (SUMM)

  • There is currently no data for SUMM

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Wednesday broker round-up UPDATE

Wed, 03rd Jul 2013 09:16

Aberdeen Asset Management: Bank of America reduces target price from 410p to 360p maintaining an underperform rating.ARM Holdings: UBS upgrades to buy from neutral, keeps target price at 970p.Cineworld: Investec ups target price from 347p to 360p and keeps a buy recommendation. N+1 Singer moves target price from 340p to 357p retaining a hold recommendation.Diageo: Espirito Santo cuts target price from 2280p to 2250p, while leaving its buy recommendation unchanged.Domino's Pizza Group: Canaccord Genuity reduces target price to 550p and downgrades to sell. Numis cuts view to add from buy. Oriel lowers to hold from add.Inchcape: Nomura takes target price from 485p to 500p staying with its neutral rating.Northgate: Goldman Sachs moves target price from 340p to 370p maintaining a neutral rating.Ocado: Jefferies raises target price from 80p to 275p, while keeping its hold recommendation.office2office: Panmure Gordon reduces target price from 120p to 67p and downgrades from buy to hold.Ophir Energy: HSBC Holdings increases target price from 530p to 558p reiterating an overweight rating.Persimmon: Deutsche Bank raises target price from 1060p to 1202p and stays with a hold recommendation. Goldman Sachs ups target price from 1756p to 1811p retaining a strong buy recommendation.PZ Cussons: Canaccord Genuity raises target price to 440p and upgrades from sell to buy.Randgold Resources: Citi increases target price from 3926p to 4491p and maintains a neutral rating.Reckitt Benckiser: Espirito Santo takes target price from 4140p to 4160p, but still recommends selling.SAB Miller: Espirito Santo reduces target price from 3520p to 3360p keeping a neutral rating.Serco Group: HSBC Holdings raises target price from 590p to 670p and upgrades to neutral.Smith (DS): Goldman Sachs lowers target price from 278p to 261p reiterating a neutral rating.Spirent Communications: Investec places both its target price (prev.: 150p) and its buy recommendation under review. Panmure Gordon moves target price from 176p to 166p, while its buy recommendation remains unchanged.Stagecoach: Morgan Stanley ups target price from 310p to 330p and retains an equal-weight rating.Summit Corporation: N+1 Singer shifts target price from 9p to 8.80p keeping a buy recommendation.Super Group: Investec increases target price from 843p to 878p leaving its buy recommendation unaltered.UNITE Group: JP Morgan moves target price from 425p to 450p and keeps an overweight rating.
More News
24 Feb 2020 10:52

Summit Therapeutics Delists In London As Focus Shifts To US

Summit Therapeutics Delists In London As Focus Shifts To US

Read more
24 Jan 2020 12:49

Summit Therapeutics Chief Operating & Medical Officer Roblin Resigns

Summit Therapeutics Chief Operating & Medical Officer Roblin Resigns

Read more
23 Jan 2020 16:47

Summit Gets More Funding For C. Difficile Infection Treatment

Summit Gets More Funding For C. Difficile Infection Treatment

Read more
24 Dec 2019 10:27

Summit Therapeutics Shuffles Board After Raising USD50 Million

Summit Therapeutics Shuffles Board After Raising USD50 Million

Read more
24 Dec 2019 09:09

Summit Therapeutics raises $40m, completes board restructuring

(Sharecast News) - Antibiotic innovation company Summit Therapeutics raised $50.0m on Tuesday by way of a subscription and placing of new ordinary shares and warrants.

Read more
17 Dec 2019 13:20

Summit Therapeutics Reports Decrease In Revenue In Third Quarter

Summit Therapeutics Reports Decrease In Revenue In Third Quarter

Read more
6 Dec 2019 13:34

Summit Therapeutics Plans Wholesale Changes As It Raises Cash

Summit Therapeutics Plans Wholesale Changes As It Raises Cash

Read more
6 Dec 2019 08:56

Summit Therapeutics raising $50m, plans to delist from AIM

(Sharecast News) - Antibiotic innovation company Summit Therapeutics announced a proposed fundraising of about $50m through a subscription and placing of new ordinary shares and warrants to existing investors on Friday, which would be subject to certain shareholder approvals being obtained and certain customary closing conditions being satisfied.

Read more
11 Oct 2019 12:53

Summit Therapeutics Sinks To Interim Loss On Ezutromid Discontinuation

Summit Therapeutics Sinks To Interim Loss On Ezutromid Discontinuation

Read more
7 Oct 2019 13:23

Summit Therapeutics Posts Explanation For Ridinilazole Trial In C Diff

Summit Therapeutics Posts Explanation For Ridinilazole Trial In C Diff

Read more
3 Oct 2019 14:23

Summit Therapeutics Reports Positive Ridinilazole Trial Results

Summit Therapeutics Reports Positive Ridinilazole Trial Results

Read more
17 Jul 2019 13:48

Summit Therapeutics New Antibiotic Shows Potential Against Gonorrhoea

(Alliance News) - Summit Therapeutics PLC on Wednesday highlighted the potential of its preclinical new class antibiotic, SMT-571, to treat gonorrhoea, at the STI & HIV World Congress in said

Read more
12 Jun 2019 13:54

Summit Therapeutics Narrows First Quarter Loss As Expenses Drop

(Alliance News) - Summit Therapeutics on Wednesday said its loss narrowed in its financial first quarter due to an increase in other operating income and a reduction in operating which develops a

Read more
15 Apr 2019 11:26

Summit Therapeutics DDS-04 Series Antibiotic Cures Infection In Study

LONDON (Alliance News) - Summit Therapeutics PLC on Monday presented proof of concept data for its DDS-04 series of antibiotics targeting Enterobacteriaceae, a family of bacteria that cause severe

Read more
15 Apr 2019 10:16

Summit Therapeutics upbeat on latest DDS-04 data

(Sharecast News) - Antibiotic innovation firm Summit Therapeutics reported on in vivo proof-of-concept data for the DDS-04 series of new mechanism antibiotics targeting enterobacteriaceae on Monday, having presented them at the 29th European Congress of Clinical Microbiology and Infectious Diseases in Amsterdam.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.